<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rivastigmine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rivastigmine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rivastigmine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11031" href="/d/html/11031.html" rel="external">see "Rivastigmine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218918"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Exelon</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868178"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Rivastigmine;</li>
<li>Exelon;</li>
<li>JAMP Rivastigmine;</li>
<li>MED-Rivastigmine;</li>
<li>MYLAN-Rivastigmine;</li>
<li>Rivastigmine Patch 10;</li>
<li>Rivastigmine Patch 15;</li>
<li>Rivastigmine Patch 5;</li>
<li>SANDOZ Rivastigmine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F218950"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor (Central)</li></ul></div>
<div class="block doa drugH1Div" id="F218923"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7c304b0-72c7-4436-a0bd-6c76c9e7d6bc">Alzheimer disease, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease, mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg/dose) every 2 weeks based on tolerability (maximum recommended dose: 6 mg twice daily).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting), and consider reducing the dose if such toxicities develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If GI adverse events occur, discontinue treatment for several doses then restart at the same or next lower dosage level; antiemetics have been used to control GI symptoms. If dosing is interrupted for ≤3 days, restart the treatment at the same or lower dose and titrate as previously described. If interrupted for &gt;3 days, reinitiate at 1.5 mg twice daily and titrate as previously described.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal patch:</b> Initial: 4.6 mg per 24 hours patch applied once daily; after a minimum of 4 weeks, increase as tolerated to 9.5 mg per 24 hours; continue as long as therapeutically beneficial. After a minimum of 4 weeks, may increase as tolerated to a maximum dose of 13.3 mg per 24 hours. Doses &gt;13.3 mg per 24 hours have not been shown to be more effective and are associated with significant increases in adverse events. Recommended effective dose: 9.5 mg per 24 hours or 13.3 mg per 24 hours patch applied once daily; remove old patch and replace with a new patch every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hour if such toxicities develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If dosing is interrupted for ≤3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hours and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Conversion from oral therapy: If oral daily dose &lt;6 mg, switch to 4.6 mg/24 hours patch; if oral daily dose 6 to 12 mg, switch to 9.5 mg/24 hours patch. Apply patch on the day following last oral dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d3f6db3-caf7-419b-9411-a9490e90d543">Alzheimer disease, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease, severe: Transdermal patch: </b>Initial: Apply 4.6 mg per 24 hours patch once daily. Increase as tolerated every 4 weeks to a maximum of 13.3 mg per 24 hours. Recommended effective dose: 13.3 mg per 24 hours patch applied once daily; remove old patch and replace with a new patch every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hours if such toxicities develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If dosing is interrupted for ≤3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hour and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3406ee01-8d87-4d65-9d08-17442b7c9c89">Dementia with Lewy bodies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dementia with Lewy bodies (off-label use):</b>
<b>Oral:</b> Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg per dose) every 2 weeks based on tolerability up to a maximum of 6 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11145488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11145488'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46642acc-b901-454c-8f0a-c7f76272d6f7">Parkinson disease dementia, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease dementia, mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg per dose) every 4 weeks based on tolerability (maximum recommended dose: 6 mg twice daily).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the dose if such toxicities develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If GI adverse events occur, discontinue treatment for several doses then restart at the same or next lower dosage level; antiemetics have been used to control GI symptoms. If dosing is interrupted for ≤3 days, restart the treatment at the same or lower dose and titrate as previously described. If interrupted for &gt;3 days, reinitiate at 1.5 mg twice daily and titrate as previously described.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal patch:</b> Initial: 4.6 mg per 24 hours patch applied once daily; after a minimum of 4 weeks, increase as tolerated to 9.5 mg per 24 hours; continue as long as therapeutically beneficial. After a minimum of 4 weeks, may increase as tolerated to a maximum dose of 13.3 mg per 24 hours. Doses &gt;13.3 mg per 24 hours have not been shown to be more effective and are associated with significant increases in adverse events. Recommended effective dose: 9.5 mg per 24 hours or 13.3 mg per 24 hours patch applied once daily; remove old patch and replace with a new patch every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hour if such toxicities develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If dosing is interrupted for ≤3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hours and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c37ada3-619b-4368-b14e-0fdb5df75333">Vascular dementia, comorbid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vascular dementia, comorbid (off-label use):</b>
<b>Note:</b> For use in patients with suspected comorbid Alzheimer disease, Parkinson disease dementia, or dementia with Lewy bodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1.5 mg twice daily for 4 weeks; may increase dose based on response and tolerability in increments of 3 mg/day (1.5 mg/dose) every 4 weeks up to a maximum of 6 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18674411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18674411'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991376"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Moderate to severe impairment (CrCl ≤50 mL/minute): There are no dosage adjustments provided in the manufacturer's labeling; patients may only be able to tolerate lower doses. Alternatively, an initial dose of 1.5 mg once daily with slow and cautious titration has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Exelon.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Exelon.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988498"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A and B): There are no dosage adjustments provided in the manufacturer's labeling; clearance is reduced and patients may require lower doses. Alternatively, an initial dose of 1.5 mg once daily with slow and cautious titration has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Exelon.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Exelon.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A and B): Initial and maximum dose: 4.6 mg/24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F218924"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Following oral administration, clearance is reduced in patients &gt;60 years of age, but dosage adjustments are not required. Age was not associated with increased exposure in patients treated transdermally.</p></div>
<div class="block arsc drugH1Div" id="F57318948"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase inhibitors, including rivastigmine, have been associated with cardiac effects, such as conduction abnormalities (eg, <b>bradycardia</b>, <b>atrioventricular block</b>, arrhythmias) and <b>hypertension</b>. <b>Syncope </b>has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16805745','lexi-content-ref-29851022','lexi-content-ref-21648211','lexi-content-ref-26691714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16805745','lexi-content-ref-29851022','lexi-content-ref-21648211','lexi-content-ref-26691714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to the mechanism of action; increased cholinergic activity results in vagotonic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20021294','lexi-content-ref-29851022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20021294','lexi-content-ref-29851022'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; reported months to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16805745','lexi-content-ref-29851022','lexi-content-ref-21648211','lexi-content-ref-26691714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16805745','lexi-content-ref-29851022','lexi-content-ref-21648211','lexi-content-ref-26691714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022','lexi-content-ref-26691714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022','lexi-content-ref-26691714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiovascular disease (eg, ischemic heart disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiac conduction abnormalities or sick sinus syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.1','lexi-content-ref-18340692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.1','lexi-content-ref-18340692'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of stroke or transient ischemic attack, diabetes, or syncope (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hernandez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hernandez.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antihypertensives (especially beta-blockers), antiarrhythmics, antidepressants, and antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29851022','lexi-content-ref-26691714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29851022','lexi-content-ref-26691714'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Application-site irritation</b> is the most common cutaneous reaction associated with transdermal rivastigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21623641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21623641'])">Ref</a></span>). In addition, <b>allergic contact dermatitis</b> may occur following oral and transdermal administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21274348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21274348'])">Ref</a></span>). Other cutaneous reactions that have been described include <b>angioedema </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620690'])">Ref</a></span>), <b>skin rash</b> (symmetric drug-related intertriginous and flexural exanthema [SDRIFE]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21469764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21469764'])">Ref</a></span>) and <b>erythematous maculopapular rash </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19889118','lexi-content-ref-11705442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19889118','lexi-content-ref-11705442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including rashes (eg, maculopapular) and allergic contact dermatitis are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21469764','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21469764','lexi-content-ref-26339470'])">Ref</a></span>); may be triggered by rivastigmine and/or excipients within the patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29620690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29620690'])">Ref</a></span>). Sensitization may occur from repeated application in the same area. Transdermal rivastigmine contains polyisobutylene, which is a known contact sensitizer and has been associated with allergic contact dermatitis from stoma bags (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8930483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8930483'])">Ref</a></span>). Application-site irritation is caused by direct toxic effect on epidermal keratinocytes, which trigger the innate immune system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30293200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30293200'])">Ref</a></span>). A positive patch test, positive rechallenge with oral drug, and response to desensitization also suggest a possible immunological mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21274348','lexi-content-ref-6503214','lexi-content-ref-19889118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21274348','lexi-content-ref-6503214','lexi-content-ref-19889118'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied; most reactions occurred within 5 to 15 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21274348','lexi-content-ref-19889118','lexi-content-ref-11705442','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21274348','lexi-content-ref-19889118','lexi-content-ref-11705442','lexi-content-ref-26339470'])">Ref</a></span>). Application-site irritation may occur within 12 hours of application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21274348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21274348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between acetylcholinesterase inhibitors is unknown. A potential cross-reaction between transdermal rivastigmine and oral galantamine has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25333552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25333552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults are at an increased risk of irritant contact dermatitis, but not allergic contact dermatitis, due to thinner and more fragile skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25684069','lexi-content-ref-21623641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25684069','lexi-content-ref-21623641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of eczema may increase risk of irritant contact dermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21623641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21623641'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects and weight loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-related GI effects are the most common adverse reactions associated with rivastigmine. Symptoms may include <b>nausea</b>, <b>vomiting</b>, <b>diarrhea, </b>and <b>abdominal pain </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20021294','lexi-content-ref-18686744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20021294','lexi-content-ref-18686744'])">Ref</a></span>). A systematic review of studies reported more GI effects with oral rivastigmine compared to donepezil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19893314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19893314'])">Ref</a></span>). In another study, oral rivastigmine had the highest rate of GI effects compared to both donepezil and galantamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18686744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18686744'])">Ref</a></span>). GI effects typically occur with dose titration and are transient and self-limiting; however, <b>dehydration, weight loss, decreased appetite</b>, and/or <b>anorexia</b> may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20021294','lexi-content-ref-14587496','lexi-content-ref-17646619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20021294','lexi-content-ref-14587496','lexi-content-ref-17646619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to mechanism of action. Increased cholinergic activity increases smooth muscle contraction, peristalsis, and sphincter relaxation in the GI tract, leading to GI effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26234945','lexi-content-ref-27261502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26234945','lexi-content-ref-27261502'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> GI effects: Rapid during dose titration; one study reported GI effects within the first 1 or 2 doses following dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20021294','lexi-content-ref-14587496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20021294','lexi-content-ref-14587496'])">Ref</a></span>). Weight loss/anorexia: Varied; may occur from the beginning of treatment to any time within the first year of therapy. More research is needed in this area, especially beyond 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16553494','lexi-content-ref-26234945','lexi-content-ref-27261502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16553494','lexi-content-ref-26234945','lexi-content-ref-27261502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral versus transdermal formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20021294','lexi-content-ref-17646619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20021294','lexi-content-ref-17646619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lack of retitration following prolonged (&gt;3 days) treatment interruption</p>
<p style="text-indent:-2em;margin-left:6em;">• Females</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients weighing &lt;50 kg</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218889"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 13%; transdermal: 2%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, anorexia (≤17%)<span class="lexi-table-link-container"> (<a aria-label="Anorexia table link" class="lexi-table-link" data-table-id="lexi-content-anorexia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anorexia')">table 2</a>)</span><span class="table-link" style="display:none;">Anorexia</span>, diarrhea (oral: 5% to 19%; transdermal: ≤7%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 3</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (oral: 23% to 47%; transdermal: 2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 4</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (oral: 17% to 31%; transdermal: 2% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 5</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anorexia" frame="border" id="lexi-content-anorexia" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Anorexia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "anorexia/decreased appetite"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "anorexia/decreased appetite"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4.6 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">47%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4.6 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4.6 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site erythema (transdermal: 1% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (transdermal: 1% to 14%), dizziness (oral: 6% to 21%; transdermal: ≤3%), headache (oral: 4% to 17%; transdermal: ≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (oral: ≥1%), hypertension (1% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 6</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, syncope (oral: 3%)<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 7</a>)</span><span class="table-link" style="display:none;">Syncope</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (oral: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (2%)<span class="lexi-table-link-container"> (<a aria-label="Dehydration table link" class="lexi-table-link" data-table-id="lexi-content-dehydration" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dehydration')">table 8</a>)</span><span class="table-link" style="display:none;">Dehydration</span>, weight loss (1% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 9</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dehydration" frame="border" id="lexi-content-dehydration" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Dehydration</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,189</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">868</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4.6 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (≤9%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-appetite')">table 10</a>)</span><span class="table-link" style="display:none;">Decreased Appetite</span>, dyspepsia (oral: 9%), sialorrhea (oral: 1%), upper abdominal pain (≤4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Appetite" frame="border" id="lexi-content-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Rivastigmine: Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Rivastigmine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "anorexia/decreased appetite"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">179</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">291</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "anorexia/decreased appetite"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">283</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9.5 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild-to-moderate Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13.3 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4.6 mg per 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe Alzheimer disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">359</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (transdermal: ≤2%), urinary tract infection (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site irritation (severe; transdermal: ≤2%), application-site pruritus (transdermal: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (1% to 3%), anxiety (1% to 5%), asthenia (2% to 6%), cogwheel rigidity (oral: 1%), confusion (oral: 8%), depression (2% to 6%), drowsiness (oral: 4% to 5%), falling (3% to 8%), fatigue (2% to 9%), hallucination (2% to 5%), insomnia (1% to 9%), malaise (oral: 5%), parkinsonism (oral: 2%), psychomotor agitation (transdermal: 1% to 3%), restlessness (oral: 3%), tremor (oral: 4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia (oral: 3%), hypokinesia (oral: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrioventricular block</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dystonia (Diaz 2015)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis (including disseminated allergic dermatitis) (Grieco 2011), erythematous maculopapular rash (Makris 2010), skin blister, skin rash (symmetric drug-related intertriginous and flexural exanthema [SDRIFE]) (Allain-Veyrac 2011), Stevens-Johnson syndrome, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Severe vomiting (with esophageal rupture; following inappropriate reinitiation of dose)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Mumoli 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Naharci 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Nightmares, seizure (Kumlien 2010)</p></div>
<div class="block coi drugH1Div" id="F218902"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to rivastigmine, other carbamate derivatives, or any component of the formulation; history of application-site reactions with rivastigmine patch</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hepatic impairment; history of severe skin reactions (eg, allergic dermatitis [disseminated], Stevens-Johnson syndrome) with oral or transdermal rivastigmine; history of QT prolongation and/or torsades de pointes, including congenital long QT syndromes; history of cardiac arrhythmias.</p></div>
<div class="block war drugH1Div" id="F218886"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extrapyramidal effects: May exacerbate or induce extrapyramidal symptoms; worsening of symptoms (eg, tremor) in patients with Parkinson disease has been observed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); may increase gastric acid secretion. Monitor for symptoms of active or occult bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with COPD and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction; cholinomimetics may cause or worsen outflow obstructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Postmarketing cases of overdose (including rare fatalities) have been reported in association with medication errors/improper use of rivastigmine transdermal patches. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch.</p></div>
<div class="block foc drugH1Div" id="F218897"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 mg, 3 mg, 4.5 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exelon: 4.6 mg/24 hr (1 ea, 30 ea); 9.5 mg/24 hr (1 ea, 30 ea); 13.3 mg/24 hr (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.6 mg/24 hr (1 ea, 30 ea); 9.5 mg/24 hr (1 ea, 30 ea); 13.3 mg/24 hr (1 ea, 30 ea)</p></div>
<div class="block geq drugH1Div" id="F218882"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F218903"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Rivastigmine Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $0.70 - $4.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $0.70 - $4.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg (per each): $0.70 - $4.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $0.70 - $4.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 24-hour</b> (Exelon Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.6 mg/24 hrs (per each): $27.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.5 mg/24 hrs (per each): $27.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.3 mg/24 hrs (per each): $27.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 24-hour</b> (Rivastigmine Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.6 mg/24 hrs (per each): $16.20 - $16.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.5 mg/24 hrs (per each): $16.20 - $16.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.3 mg/24 hrs (per each): $16.20 - $16.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868179"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exelon: 1.5 mg, 3 mg, 4.5 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 mg, 3 mg, 4.5 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exelon: 4.6 mg/24 hr (30 ea); 9.5 mg/24 hr (30 ea); 13.3 mg/24 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivastigmine Patch 5: 4.6 mg/24 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivastigmine Patch 10: 9.5 mg/24 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivastigmine Patch 15: 13.3 mg/24 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.6 mg/24 hr (30 ea); 9.5 mg/24 hr (30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Exelon: 2 mg/mL (120 mL) [contains sodium benzoate]</p></div>
<div class="block adm drugH1Div" id="F218899"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with meals (breakfast and dinner). Oral solution [Canadian product], which is available for patients who cannot swallow capsules, can be swallowed directly from syringe or mixed with water, soda, or cold fruit juice. Stir well and drink immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Apply transdermal patch to upper or lower back (alternatively, may apply to upper arm or chest). Do not use patch if the pouch seal is broken or if the patch is cut, altered, or damaged. Avoid reapplication to same spot of skin for 14 days (eg, may rotate sections of back). Apply to clean, dry, and hairless skin. Patch should be pressed down firmly by applying pressure with the hand over the entire patch for at least 30 seconds, making sure edges stick well. Do not apply to red, irritated, or broken skin. Avoid areas of recent application of lotion or powder. After removal, fold patch to press adhesive surfaces together, place in previously saved pouch, and discard. Avoid eye contact; wash hands after handling patch. Remove old patch and replace with a new patch every 24 hours (at the same time each day). If a dose is missed or if the patch falls off, apply a new patch immediately and replace the following day at the usual application time. Do not use overlays, bandages, or tape to secure a patch that has become loose. Avoid exposing the patch to external sources of heat (eg, sauna, excessive light) for prolonged periods of time. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch. Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.</p></div>
<div class="block use drugH1Div" id="F218898"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Treatment of mild to moderate dementia of the Alzheimer type.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Treatment of mild, moderate, and severe dementia of the Alzheimer type.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease dementia:</b> Treatment of mild to moderate dementia associated with Parkinson disease.</p></div>
<div class="block off-label drugH1Div" id="F25472189"><span class="drugH1">Use: Off-Label: Adult</span><p>Dementia with Lewy bodies; Vascular dementia, comorbid</p></div>
<div class="block mst drugH1Div" id="F46860290"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Exelon may be confused with Exelan (manufacturer)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300010"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F218891"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Rivastigmine may enhance the neurotoxic (central) effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Rivastigmine may enhance the bradycardic effect of Beta-Blockers. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: Rivastigmine may enhance the adverse/toxic effect of Bromopride. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: May enhance the adverse/toxic effect of Rivastigmine. Specifically, cholinergic effects may be enhanced or increased. Rivastigmine may enhance the adverse/toxic effect of Cholinergic Agonists. Management: Use of rivastigmine with a cholinergic agonist is not recommended unless clinically necessary. If the combination is necessary, monitor for increased cholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: Rivastigmine may enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Rivastigmine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F218915"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food delays absorption by 90 minutes, lowers C<sub>max</sub> by 30% and increases AUC by 30%. Management: Administer with meals.</p></div>
<div class="block pri drugH1Div" id="F218904"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F13907415"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if rivastigmine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F218895"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cognitive function at periodic intervals, symptoms of GI intolerance, decreased weight, signs of cutaneous reactions.</p></div>
<div class="block pha drugH1Div" id="F218885"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A deficiency of cortical acetylcholine is thought to account for some of the symptoms of Alzheimer disease and Parkinson disease dementia; rivastigmine increases acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by cholinesterase</p></div>
<div class="block phk drugH1Div" id="F218901"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Anticholinesterase activity (CSF): ~10 hours (6 mg oral dose)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Fasting: Rapid and complete within 1 hour; Transdermal patch: Within 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 1.8 to 2.7 L/kg; penetrates blood-brain barrier (CSF levels are ~40% of plasma levels following oral administration) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 40% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively via cholinesterase-mediated hydrolysis in the brain; metabolite undergoes N-demethylation and/or sulfate conjugation hepatically; CYP minimally involved; linear kinetics at 3 mg twice daily, but nonlinear at higher doses </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 36%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Oral: 1.5 hours; Transdermal patch: ~3 hours (after removal) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: 1 hour; Transdermal patch: 8 to 16 hours following first dose </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (97% as metabolites); feces (0.4%)</p></div>
<div class="block phksp drugH1Div" id="F51159816"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment: Mean oral clearance is 64% lower.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Mean oral clearance is 43% higher for unexplained reasons.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Mean oral clearance is 60% lower.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean oral clearance was 30% lower.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Oral clearance increases 23%.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Exposure is higher in patients with low body weight (&lt;50 kg) and lower in patients with an increased body weight (&gt;100 kg).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218906"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Luneste | Remizeral | Rivasmina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Nimvastid | Rivagelan | Rivastigmin 1a pharma | Rivastigmin Genericon | Rivastigmin kappler | Rivastigmin ratiopharm | Rivastigmin sandoz | Rivastigmin Sandoz | Rivastigmin stada | Rivastigmine actavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Exelon patch 10 | Exelon Patch 5 | Rivastigmelon</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Benzenod | Exelon | Rivacap | Rivamer | Vastigro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Niddastig | Rivastigmine apotex | Rivastigmine mylan | Rivastigmine Mylan | Rivastigmine sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Ridaxin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Hemitartarato de rivastigmina | Hidrogenotartarato de rivastigmina | Prometax | Rivastelon | Rivastigmina | Tigma | Vastigma | Vivencia</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmin mepha | Rivastigmin zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Probrain | Rivazic</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Astigmin | Exelon | Neuract | Prometax | Rivamer</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Evertas | Exelon | Ristidic | Rivastigmin +pharma | Rivastigmin orion | Rivastigmin Ratiopharm | Vastigmex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Miestigacin | Nimvastid | Prometax | Rivastigmin | Rivastigmin 1a pharma | Rivastigmin Acino | Rivastigmin actavis | Rivastigmin Aurobindo | Rivastigmin Beta | Rivastigmin betapharm | Rivastigmin Biomo | Rivastigmin delorbis | Rivastigmin dura | Rivastigmin Heuman | Rivastigmin heumann | Rivastigmin hexal | Rivastigmin Hormosan | Rivastigmin Neurax | Rivastigmin Neuraxpharm | Rivastigmin Pfizer | Rivastigmin ratiopharm | Rivastigmin stada | Rivastigmin teva | Rivastigmin zentiva | Rivastigmine acino | Rivastigmine aristo | Rivastigmine hexal | Rivendo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Exelom | Exelon</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivazic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmin orion</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivamash | Rivamep | Rivastalone | Rivaxel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alzerta | Demelora | Exelon | Nimvastid | Nofleban | Prometax | Rivanex | Rivastigmina Apotex | Rivastigmina apotex | Rivastigmina aristo | Rivastigmina aurobindo | Rivastigmina aurovitas | Rivastigmina Cinfa | Rivastigmina cinfa | Rivastigmina Combix | Rivastigmina farmalider | Rivastigmina Kern | Rivastigmina Kern pharma | Rivastigmina lorien | Rivastigmina mylan | Rivastigmina Normon | Rivastigmina normon | Rivastigmina ortodrol | Rivastigmina ratiopharm | Rivastigmina Sandoz | Rivastigmina stada | Rivastigmina tecnigen | Rivastigmina teva | Rivastigmina travel | Rivastigmina vir | Rivastigmina zentiva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Nimvastid | Rivastigmin orifarm | Rivastigmin orion | Rivastigmin Ratiopharm | Rivastigmin ratiopharm | Rivastigmin Sandoz | Rivastigmine actavis | Rivastigmine Stada | Rivastor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmine actavis | Rivastigmine arrow | Rivastigmine Biogaran | Rivastigmine eg | Rivastigmine EG | Rivastigmine mylan | Rivastigmine Mylan | Rivastigmine sandoz | Rivastigmine teva | Rivastigmine viatris | Rivastigmine zentiva | Rivastigmine Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Almuriva | Alzest | Eluden | Erastig | Exelon | Kerstipon | Nimvastid | Prometax | Rivastigmine | Rivastigmine actavis | Rivastigmine Rosemont | Rivatev | Somniton | Voleze</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alapril | Balaxon | Evertas | Exelon | Immitis | Impalon | Lasium | Mentazac | Rivagmin | Rivanel | Rivaset | Rivastigmine zentiva | Rivastigmine/adelco | Rivastigmine/generics | Rivetal | Vialon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo Rivastigmine | Exelon | Exelon patch 10 | Exelon Patch 5 | Rivasan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Nimvastid | Rivastigmine | Rivastigmine Mylan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivadem | Rivamer | Rivasmine | Rivera</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Demelora | Exelon | Nimvastid | Prometax | Rivastigmina | Rivastigmina Actavis | Rivastigmina doc | Rivastigmina Sandoz | Rivastigmina zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivaxel | Rivetal | Stegmex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastach</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Altsustigmine | Ausgmine | Brexell | Demencure | Denuvo | Dimenlis | Dongkoo rivastigmine tartrate | Eusbera | Excel c | Exelon | Exelon patch 10 | Exelon patch 15 | Exelon Patch 5 | Exelriva | Exolon | Huons rivastigmine | Inist rivastigmine | Listamin patch 10 | Listamin patch 5 | Livafiron patch 10 | Livafiron patch 5 | Monsti | Nectimine | Newxelon | Oselon | Rigmin | Riselton | Risti | Rivaderm | Rivaglon | Rivagmine | Rivamensa | Rivameron | Rivamine | Rivaminine | Rivapet | Rivaron | Rivas | Rivaslon | Rivasmin | Rivastigmine bkw | Rivastiren | Rivatimine | Rivawins | Rivaxelon | Rivaxen | Samsung rivastigmine | Samyang biopharm rivastigmine | Sinsin rivastigmine | Stagmin | Stelron | Stigma | Uniriva | Uniselon | Wondron 10 | Wondron 15 | Wondron 5</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmine arrow</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Evertas | Exelon | Rivastigmin | Rivastigmin ratiopharm | Rivastigmine hexal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmin actavis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Demsilev | Exelon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivadem | Rivamensa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Demelora | Exelon | Permente | Rivaldo tds | Rivastigmine actavis | Rivastigmine aurobindo | Rivastigmine cf | Rivastigmine Mylan | Rivastigmine mylan | Rivastigmine neuraxpharm | Rivastigmine ratiopharm | Rivastigmine sandoz | Rivastigmine teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Orivast | Rivastigmin orion | Rivastigmine Teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivamer | Tafcilex-10 | Tafcilex-5</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivadem</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Memomax | Ridaxin | Rivagem | Rivamer | Rivastat | Rivastig | Riveme | Rivsaff</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Evertas | Exelon | Nimvastid | Permente | Prometax | Ristidic | Rivaldo | Rivaldo tds | Rivastigmin orion | Rivastigmin stada | Rivastigmine actavis | Rivastigmine Mylan | Rivastigmine Teva | Rivastigmine teva | Rivaxon | Riveka | Rywastygmina apotex | Rywastygmina neuraxpharm | Signelon | Symelon | Vergesin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmine | Rivastigmine tartrate | Rivastigmine Transdermal system</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Prometax | Rivastigmina aurobindo | Rivastigmina Bluepharma | Rivastigmina Ciclum | Rivastigmina generis | Rivastigmina Generis | Rivastigmina Labesfal | Rivastigmina mylan | Rivastigmina pentafarma | Rivastigmina Sandoz | Rivastigmina teva | Rivastigmina toLife | Rivastigmina zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Exelon 10 | Exelon 5</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Evertas | Exelon | Nimvastid | Ridaxin | Rivastigmina dr. reddy's | Rivastigmina teva | Rivastigmine sandoz</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alcenorm | Exelon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivetal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Nimvastid | Orivast | Prometax | Rigmin | Rivastigmin abacus medicine | Rivastigmin ebb | Rivastigmin orifarm | Rivastigmin orion | Rivastigmin Sandoz | Rivastigmin stada | Rivastigmine actavis | Rivastigmine sandoz | Rivastor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Exelon</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivastigmin | Rivastigmin teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Evertas | Exelon | Ristidic | Rivastigmin +pharma | Rivastigmin orion | Rivastigmine Teva | Vastigmex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivasta | Trivacin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivetal | Vitacholine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Altigmin | Exelon | Ristart | Rivarem | Rivaxel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Revelin | Ristig | Rivast</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rivastigmin IC | Rivastigmin orion</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Amizeral | Exelon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Rivamer</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Exelon | Kyriz</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21469764">
<a name="21469764"></a>Allain-Veyrac G, Lebreton A, Collonnier C, Jolliet P. First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? <i>Am J Clin Dermatol</i>. 2011;12(3):210-213. doi:10.2165/11318350-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21469764/pubmed" id="21469764" target="_blank">21469764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25684069">
<a name="25684069"></a>Alva G, Cummings JL, Galvin JE, Meng X, Velting DM. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. <i>Int J Clin Pract</i>. 2015;69(5):518-530. doi:10.1111/ijcp.12621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/25684069/pubmed" id="25684069" target="_blank">25684069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30293200">
<a name="30293200"></a>Bains SN, Nash P, Fonacier L. Irritant contact dermatitis. <i>Clin Rev Allergy Immunol</i>. 2019;56(1):99-109. doi:10.1007/s12016-018-8713-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/30293200/pubmed" id="30293200" target="_blank">30293200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16805745">
<a name="16805745"></a>Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. <i>Int J Clin Pract</i>. 2006;60(6):639-645. doi:10.1111/j.1368-5031.2006.00967.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/16805745/pubmed" id="16805745" target="_blank">16805745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18674411">
<a name="18674411"></a>Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Curr Med Res Opin</i>. 2008;24(9):2561-2574. doi:10.1185/03007990802328142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/18674411/pubmed" id="18674411" target="_blank">18674411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23728651">
<a name="23728651"></a>Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. <i>Cochrane Database Syst Rev</i>. 2013;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/23728651/pubmed" id="23728651" target="_blank">23728651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20021294">
<a name="20021294"></a>Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. <i>Expert Opin Drug Saf</i>. 2010;9(1):167-176. doi:10.1517/14740330903439717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/20021294/pubmed" id="20021294" target="_blank">20021294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26313774">
<a name="26313774"></a>Diaz MCB, Rosales RL. A case report on dyskinesia following rivastigmine patch 13.3 mg/24 hours for Alzheimer's Disease: perspective in the movement disorders spectrum following use of cholinesterase inhibitors. <i>Medicine (Baltimore)</i>. 2015;94(34):e1364. doi:10.1097/MD.0000000000001364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/26313774/pubmed" id="26313774" target="_blank">26313774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15590953">
<a name="15590953"></a>Emre M, Aarsland D, Albanese A, et al, “Rivastigmine for Dementia Associated with Parkinson’s Disease,” <i>N Engl J Med</i>, 2004, 351(24):2509-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/15590953/pubmed" id="15590953" target="_blank">15590953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exelon.2">
<a name="Exelon.2"></a>Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exelon.3">
<a name="Exelon.3"></a>Exelon capsules and oral solution (rivastigmine) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Exelon.4">
<a name="Exelon.4"></a>Exelon Patch (rivastigmine) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14587496">
<a name="14587496"></a>Farlow MR. Update on rivastigmine. <i>Neurologist</i>. 2003;9(5):230-234. doi:10.1097/01.nrl.0000087724.73783.5f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/14587496/pubmed" id="14587496" target="_blank">14587496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25333552">
<a name="25333552"></a>Golüke NM, van Strien AM, Dautzenberg PJ, Jessurun N, Keijsers CJ. Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report. <i>J Am Geriatr Soc</i>. 2014;62(10):2012-2013. doi:10.1111/jgs.13045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/25333552/pubmed" id="25333552" target="_blank">25333552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11495394">
<a name="11495394"></a>Grace J, Daniel S, Stevens T, et al, “Long Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open Label Trial,” <i>Int Psychogeriatr</i>, 2001, 13(2):199-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/11495394/pubmed" id="11495394" target="_blank">11495394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21623641">
<a name="21623641"></a>Greenspoon J, Herrmann N, Adam DN. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. <i>CNS Drugs</i>. 2011;25(7):575-583. doi:10.2165/11592230-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21623641/pubmed" id="21623641" target="_blank">21623641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534872">
<a name="31534872"></a>Greiman TL, Dear BN, Wilkening GL. Adverse outcomes of abrupt switch and discontinuation of acetylcholinesterase inhibitors in dementia with Lewy bodies: case report and literature review. <i>Ment Health Clin</i>. 2019;9(5):309-314. doi:10.9740/mhc.2019.09.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/31534872/pubmed" id="31534872" target="_blank">31534872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21274348">
<a name="21274348"></a>Grieco T, Rossi M, Faina V, De Marco I, Pigatto P, Calvieri S. An atypical cutaneous reaction to rivastigmine transdermal patch.<i> J Allergy (Cairo)</i>. 2011;2011:752098. doi:10.1155/2011/752098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21274348/pubmed" id="21274348" target="_blank">21274348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6503214">
<a name="6503214"></a>Groth H, Vetter H, Knüsel J, Foerster E, Siegenthaler W, Vetter W. Transdermal clonidine application: long-term results in essential hypertension. <i>Klin Wochenschr</i>. 1984;62(19):925-930. doi:10.1007/BF01727445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/6503214/pubmed" id="6503214" target="_blank">6503214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18686744">
<a name="18686744"></a>Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. <i>Clin Interv Aging</i>. 2008;3(2):211-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/18686744/pubmed" id="18686744" target="_blank">18686744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hernandez.1">
<a name="Hernandez.1"></a>Hernandez I. Risk factors for cardiovascular events of antidementia drugs in Alzheimer's disease patients. <i>Journal of Clinical Gerontology &amp; Geriatrics</i>. 2016; 77-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/Hernandez.1/pubmed" id="Hernandez.1" target="_blank">Hernandez.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831773">
<a name="20831773"></a>Hort J, O'Brien JT, Gainotti G, et al, “EFNS Guidelines for the Diagnosis and Management of Alzheimer’s Disease,” <i>Eur J Neurol</i>, 2010, 17(10):1236-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/20831773/pubmed" id="20831773" target="_blank">20831773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553494">
<a name="16553494"></a>Hughes A, Musher J, Thomas SK, Beusterien KM, Strunk B, Arcona S. Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. <i>Consult Pharm</i>. 2004;19(8):713-720. doi:10.4140/tcp.n.2004.713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/16553494/pubmed" id="16553494" target="_blank">16553494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29851022">
<a name="29851022"></a>Isik AT, Soysal P, Stubbs B, et al. Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review. <i>J Am Geriatr Soc</i>. 2018;66(9):1805-1811. doi:10.1111/jgs.15415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/29851022/pubmed" id="29851022" target="_blank">29851022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20036167">
<a name="20036167"></a>Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. <i>Seizure</i>. 2010;19(2):69-73. doi: 10.1016/j.seizure.2009.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/20036167/pubmed" id="20036167" target="_blank">20036167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522596">
<a name="17522596"></a>Lefevre G, Sedek G, Jhee SS, et al, “Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients,” <i>Clin Pharmacol Ther</i>, 2008, 83(1):106-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/17522596/pubmed" id="17522596" target="_blank">17522596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19893314">
<a name="19893314"></a>Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. <i>Dement Geriatr Cogn Disord</i>. 2009;28(5):389-403. doi:10.1159/000255578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/19893314/pubmed" id="19893314" target="_blank">19893314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19889118">
<a name="19889118"></a>Makris M, Koulouris S, Koti I, Aggelides X, Kalogeromitros D. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization. <i>Allergy</i>. 2010;65(7):925-926. doi:10.1111/j.1398-9995.2009.02258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/19889118/pubmed" id="19889118" target="_blank">19889118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11145488">
<a name="11145488"></a>McKeith I, Del Ser T, Spano P, et al, “Efficacy of Rivastigmine in Dementia With Lewy Bodies: A Randomised, Double-Blind, Placebo-Controlled International Study,” <i>Lancet</i>, 2000, 356(9247):2031-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/11145488/pubmed" id="11145488" target="_blank">11145488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16606910">
<a name="16606910"></a>Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2006;66(7):996-1002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/16606910/pubmed" id="16606910" target="_blank">16606910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11705442">
<a name="11705442"></a>Monastero R, Lopez G, Mannino M, Camarda R. Erythematous maculopapular eruption due to rivastigmine therapy. <i>Am J Med</i>. 2001;111(7):583-584. doi:10.1016/s0002-9343(01)00920-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/11705442/pubmed" id="11705442" target="_blank">11705442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19888250">
<a name="19888250"></a>Mumoli N, Carmignani G, Luschi R, Cei M, Chiavistelli P. Hepatitis with cholestasis caused by rivastigmine transdermal patch. <i>Am J Gastroenterol</i>. 2009;104(11):2859-2860. doi: 10.1038/ajg.2009.373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/19888250/pubmed" id="19888250" target="_blank">19888250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620690">
<a name="29620690"></a>Naharci MI, Tasci I. Angioedema caused by rivastigmine patch: a rare case. <i>J Clin Psychopharmacol</i>. 2018;38(3):281-282. doi:10.1097/JCP.0000000000000875<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/29620690/pubmed" id="29620690" target="_blank">29620690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline 97. https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28103749">
<a name="28103749"></a>O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2017;31(2):147-168. doi: 10.1177/0269881116680924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/28103749/pubmed" id="28103749" target="_blank">28103749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8930483">
<a name="8930483"></a>Parslew R, Evans S, King CM. Allergic contact dermatitis from polyisobutylene in stoma bags. <i>Contact Dermatitis</i>. 1996;35(3):178-179. doi:10.1111/j.1600-0536.1996.tb02341.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/8930483/pubmed" id="8930483" target="_blank">8930483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21648211">
<a name="21648211"></a>Prescrire Int. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. <i>Prescrire Int</i>. 2011;20(115):95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21648211/pubmed" id="21648211" target="_blank">21648211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al, “American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,” <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Rivastigmine tartrate capsules (rivastigmine) [prescribing information]. Ahmedabad, Gujarat, India: Cadila Pharmaceuticals Limited; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26234945">
<a name="26234945"></a>Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. <i>J Am Geriatr Soc</i>. 2015;63(8):1512-1518. doi: 10.1111/jgs.13511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/26234945/pubmed" id="26234945" target="_blank">26234945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26691714">
<a name="26691714"></a>Soysal P, Isik AT. Asymptomatic bradycardia due to rivastigmine in an elderly adult with Lewy Body Dementia. <i>J Am Geriatr Soc</i>. 2015;63(12):2648-2650. doi:10.1111/jgs.13858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/26691714/pubmed" id="26691714" target="_blank">26691714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27261502">
<a name="27261502"></a>Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. <i>J Neurol Neurosurg Psychiatry</i>. 2016;87(12):1368-1374. doi:10.1136/jnnp-2016-313660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/27261502/pubmed" id="27261502" target="_blank">27261502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21056464">
<a name="21056464"></a>van Eijk MM, Roes KC, Honing ML, et al, "Effect of Rivastigmine as an Adjunct to Usual Care With Haloperidol on Duration of Delirium and Mortality in Critically Ill Patients: A Multicentre, Double-Blind, Placebo-Controlled Randomised Trial," <i>Lancet</i>, 2010, 376(9755):1829-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21056464/pubmed" id="21056464" target="_blank">21056464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17380489">
<a name="17380489"></a>Winblad B, Cummings J, Andreasen N, et al, “A Six-Month Double-Blind, Randomized, Placebo-Controlled Study of a Transdermal Patch in Alzheimer's Disease − Rivastigmine Patch Versus Capsule,” <i> Int J Geriatr Psychiatry</i>, 2007a, 22(5):456-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/17380489/pubmed" id="17380489" target="_blank">17380489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17646619">
<a name="17646619"></a>Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. <i>Neurology</i>. 2007b;69(4 Suppl 1):S14-22. doi:10.1212/01.wnl.0000281847.17519.e0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/17646619/pubmed" id="17646619" target="_blank">17646619</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9529 Version 403.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
